Patents by Inventor Jurgen Bernhagen
Jurgen Bernhagen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11891456Abstract: The present invention relates to peptides, in particular amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides. Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of treating or diagnosing neurodegenerative diseases such as Alzheimer's disease, or for use in a method of treating or diagnosing type 2 diabetes. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of Alzheimer's disease or type 2 diabetes in a patient.Type: GrantFiled: October 5, 2022Date of Patent: February 6, 2024Assignee: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Aphrodite Kapurniotu, Anna Spanopoulou, Luzia Heidrich, Jürgen Bernhagen
-
Publication number: 20230242616Abstract: The present invention relates to a chemokine-selective CXCR4 ectodomain-derived (poly)peptide comprising or consisting of a first peptide of (X1)(X2)(X3)(X4)(X5)WYFGNF(X6)(X7)(X8) (SEQ ID NO: 1) linked via a linker to a second peptide of (Y1)(Y2)(Y3)(Y4)(Y5)D(Y6)FY(Y7)N(Y8)LW(Y9) (SEQ ID NO: 2), wherein (X1) is present or absent and, if present, is an amino acid, preferably D or A (X2) is present or absent and, if present, is an amino acid, preferably A or G (X3) is present or absent and, if present, is an amino acid, preferably V or A (X4) is present or absent and, if present, is an amino acid, preferably A or G (X5) is present or absent and, if present, is an amino acid, preferably N (X6) is an amino acid, preferably L or A (X7) is an amino acid, preferably C, A or S, more preferably C or A (X8) is an amino acid, preferably K or A (Y1) is present or absent and, if present, is an amino acid, preferably D or A (Y2) is present or absent and, if present, is an amino acid, preferably R or A (Y3) is present or aType: ApplicationFiled: June 15, 2021Publication date: August 3, 2023Inventors: Jürgen Bernhagen, Omar El Bounkari, Aphrodite Kapurniotu, Christos Kontos
-
Publication number: 20230095144Abstract: The present invention relates to peptides, in particular amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides. Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of treating or diagnosing neurodegenerative diseases such as Alzheimer's disease, or for use in a method of treating or diagnosing type 2 diabetes. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of Alzheimer's disease or type 2 diabetes in a patient.Type: ApplicationFiled: October 5, 2022Publication date: March 30, 2023Inventors: APHRODITE KAPURNIOTU, ANNA SPANOPOULOU, LUZIA HEIDRICH, JÜRGEN BERNHAGEN
-
Patent number: 11498943Abstract: The present invention relates to peptides, in particular amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides. Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of treating or diagnosing neurodegenerative diseases such as Alzheimer's disease, or for use in a method of treating or diagnosing type 2 diabetes. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of Alzheimer's disease or type 2 diabetes in a patient.Type: GrantFiled: June 6, 2019Date of Patent: November 15, 2022Assignee: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Aphrodite Kapurniotu, Anna Spanopoulou, Luzia Heidrich, Jürgen Bernhagen
-
Publication number: 20210340180Abstract: The present invention relates to peptides, in particular amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides. Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of treating or diagnosing neurodegenerative diseases such as Alzheimer's disease, or for use in a method of treating or diagnosing type 2 diabetes. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of Alzheimer's disease or type 2 diabetes in a patient.Type: ApplicationFiled: June 6, 2019Publication date: November 4, 2021Inventors: APHRODITE KAPURNIOTU, ANNA SPANOPOULOU, LUZIA HEIDRICH, JÜRGEN BERNHAGEN
-
Publication number: 20120149044Abstract: The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.Type: ApplicationFiled: February 24, 2012Publication date: June 14, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Richard J. Bucala, Robert A. Mitchell, Jurgen Bernhagen, Thierry F. Calandra, Anthony Cerami
-
Publication number: 20120028281Abstract: The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.Type: ApplicationFiled: July 20, 2011Publication date: February 2, 2012Inventors: Richard J. Bucala, Robert A. Mitchell, Jurgen Bernhagen, Thierry F. Calandra, Anthony Cerami
-
Publication number: 20110262386Abstract: Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF-activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof.Type: ApplicationFiled: March 20, 2009Publication date: October 27, 2011Applicant: CAROLUS THERPEUTICS, INC.Inventors: Jürgen Bernhagen, Joshua Robert Schultz, Benedikt Vollrath, Alma Zernecke, Christian Weber
-
Publication number: 20110070184Abstract: Described herein are methods for treating or preventing a atherosclerosis by inhibiting the activation or binding of macrophage migration inhibitory factor to CXCR2 and CXCR4. Such inhibition is achieved by administration of either a single agent or a combination of agents. Also described herein are agents that inhibit MIF-binding or MIF-activation of CXCR2 or CXCR4. Further described are pharmaceutical compositions comprising such agents and their use for treating or preventing atherosclerosis.Type: ApplicationFiled: March 24, 2008Publication date: March 24, 2011Applicant: CAROLUS THERPEUTICS, INC.Inventors: Jürgen Bernhagen, Christian Weber, Alma Zernecke
-
Publication number: 20110044988Abstract: Disclosed herein, in certain embodiments, is a method for treating an inflammatory disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF-activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof.Type: ApplicationFiled: March 20, 2009Publication date: February 24, 2011Applicant: CAROLUS THERPEUTICS, INC.Inventors: Jürgen Bernhagen, Joshua Robert Schultz, Benedikt Vollrath, Alma Zernecke, Christian Weber
-
Publication number: 20100221240Abstract: The present invention relates to improved agents and methods for treating diabetes and Alzheimer's disease by use of IAPP peptide derivatives.Type: ApplicationFiled: October 18, 2005Publication date: September 2, 2010Applicant: FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Afroditi Kapurniotu, Jürgen Bernhagen
-
Publication number: 20100184091Abstract: The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.Type: ApplicationFiled: June 3, 2009Publication date: July 22, 2010Applicant: Cytokine PharmaSciences, Inc.Inventors: Richard J. Bucala, Robert A. Mitchell, Jurgen Bernhagen, Thierry F. Calandra, Anthony Cerami
-
Publication number: 20090163599Abstract: The present invention concerns an apheresis material or adsorbant and a method for removing, depleting or inactivating MIF (macrophage migration inhibitory factor) from blood, blood plasma, blood serum or other body fluids. The present invention is also concerned with the use of said apheresis material or adsorbant. In order to prepare a novel means and novel method, which can reduce the activity or amount of the mediator for sepsis and septic shock, MIF, in a patient's body fluid in a manner which is more pleasant and tolerable for the patient than prior art means and methods, the invention proposes that the apheresis material or adsorbant comprises a solid carrier material on the surface of which MIF-binding molecules or functional groups are immobilized. The method proposes that the apheresis material or adsorbant be brought into contact extracorporeally with the blood, blood plasma, blood serum or other body fluids.Type: ApplicationFiled: June 3, 2005Publication date: June 25, 2009Inventors: Markus Storr, Reinhold Deppisch, Werner Beck, Jürgen Bernhagen, Ina Merz, Georg Geiger
-
Patent number: 7517523Abstract: The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.Type: GrantFiled: June 17, 2003Date of Patent: April 14, 2009Assignee: Cytokine PharmaSciences, Inc.Inventors: Richard Bucala, Robert A. Mitchell, Jurgen Bernhagen, Thierry F. Calandra, Anthony Cerami
-
Publication number: 20080146508Abstract: The invention concerns a peptide having the biological activity of an inhibitor of amyloid formation and its diagnostic and medical use.Type: ApplicationFiled: January 9, 2008Publication date: June 19, 2008Inventors: Afroditi KAPURNIOTU, Jurgen Bernhagen, Herwig Brunner
-
Patent number: 7342091Abstract: The invention concerns a peptide having the biological activity of an inhibitor of amyloid formation and its diagnostic and medical use.Type: GrantFiled: December 21, 2001Date of Patent: March 11, 2008Assignee: Fraunhofer-Gesellschaf zur Forderung der angewandten Forschung e.VInventors: Afroditi Kapurniotu, Jürgen Bernhagen, Herwig Brunner
-
Patent number: 7303885Abstract: The present invention relates to methods for screening molecules and methods to detect protein-protein interactions and means used therein. More specifically, the present invention relates to methods for screening candidate drugs for treating or detecting MIF (macrophage migration inhibitor factor) related diseases. In certain aspects, the present invention involves detecting MIF/Jab1 (c-Jun activation domain binding protein) interactions as a basis for modulating cellular regulatory pathways and for identifying candidate drugs for MIF-related diseases. The invention also provides methods for the identification of molecules which dissociate or prevent interaction or binding between MIF and Jab1.Type: GrantFiled: November 2, 2000Date of Patent: December 4, 2007Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.Inventors: Herwig Brunner, Jürgen Bernhagen, Robert Kleemann, Ralf Mischke, Afroditi Kapurniotu
-
Publication number: 20060062788Abstract: The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.Type: ApplicationFiled: September 14, 2005Publication date: March 23, 2006Inventors: Richard Bucala, Robert Mitchell, Jurgen Bernhagen, Thierry Calandra, Anthony Cerami
-
Patent number: 6998238Abstract: A diagnostic method for determining MIF protein content in a sample using a direct or an indirect detection technique and wherein MIF is a human MIF protein having a molecular weight of approximately 12.5 kDa.Type: GrantFiled: April 25, 2000Date of Patent: February 14, 2006Assignee: Cytokine PharmaSciences, Inc.Inventors: Richard J. Bucala, Robert A. Mitchell, Jurgen Bernhagen, Thierry F. Calandra, Anthony Cerami
-
Patent number: RE43497Abstract: The present invention relates to methods for screening molecules and methods to detect protein-protein interactions and means used therein. More specifically, the present invention relates to methods for screening candidate drugs for treating or detecting MIF (macrophage migration inhibitor factor) related diseases. In certain aspects, the present invention involves detecting MIF/Jab1 (c-Jun activation domain binding protein) interactions as a basis for modulating cellular regulatory pathways and for identifying candidate drugs for MIF-related diseases. The invention also provides methods for the identification of molecules which dissociate or prevent interaction or binding between MIF and Jab1.Type: GrantFiled: November 2, 2000Date of Patent: June 26, 2012Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.Inventors: Herwig Brunner, Jürgen Bernhagen, Robert Kleemann, Ralf Mischke, Afroditi Kapurniotu